Kidney Stone Risk Factors: What Raises Your Chances of Forming a Stone
Kidney stones affect approximately 1 in 11 Americans over their lifetime, with incidence rates rising steadily over the past three decades. While a kidney stone can occur in anyone, the probability of forming one is far from uniform across the population — a substantial set of modifiable and non-modifiable risk factors determines which individuals face the highest burden of stone disease, and understanding these risk factors is the foundation of evidence-based prevention. Someone who has never had a kidney stone but has multiple risk factors has a meaningfully higher probability of first-time stone formation than someone without those factors; someone who has already had a stone and has not addressed the metabolic and dietary contributors faces a 50% chance of recurrence within 5 years and 70% within 10 years without preventive intervention.
Kidney stone risk factors operate through a common final pathway: they increase the urinary concentration of stone-forming solutes (calcium, oxalate, uric acid, cystine), decrease the urinary concentration of crystallization inhibitors (citrate, magnesium), reduce urine volume (concentrating all solutes), or alter urinary pH (which controls the solubility of pH-sensitive compounds like uric acid and cystine). Most patients who form stones do not have a single dramatic risk factor but a combination of several moderate ones that collectively push urinary supersaturation above the crystallization threshold. Identifying and addressing even two or three modifiable risk factors typically produces a substantial reduction in stone-forming potential — a goal achievable for most patients through a combination of dietary modification and, when indicated, targeted pharmacological therapy.
Dehydration and Low Urine Volume
Low urine volume is the most universal kidney stone risk factor across all stone types and is present to some degree in the majority of stone formers. When urine output falls below 1.5 to 2 liters per day, the concentration of all urinary solutes increases — calcium, oxalate, uric acid, and other stone-forming compounds become more concentrated in less water, elevating the supersaturation ratio that drives crystal formation. This concentration effect occurs without any change in the absolute amount of these compounds excreted daily; a person excreting a normal amount of calcium in 800 mL of urine has a much higher calcium concentration and a much higher stone risk than the same person excreting the same calcium in 2,000 mL of urine.
Hot climates significantly amplify stone risk through dehydration. Population studies consistently show higher kidney stone incidence in warmer geographic regions — the American “stone belt” (southeastern United States) has substantially higher stone prevalence than cooler northern regions. Occupational exposure to heat — construction workers, outdoor laborers, military personnel in hot environments, athletes training in warm conditions — predisposes to chronic mild dehydration that cumulatively elevates stone risk. Seasonal patterns in stone presentations mirror heat exposure, with peaks in summer months. Air travel produces mild dehydration through low-humidity cabin air and is an underappreciated transient risk factor for stone formers with marginal fluid intake. For guidance on achieving adequate daily hydration for stone prevention, see the hydration and kidney stone prevention guide on Horizon Health Guide.
Dietary Risk Factors for Kidney Stones
High sodium intake is one of the most modifiable and most impactful dietary risk factors for calcium stones. Sodium and calcium share renal tubular transport mechanisms — when sodium reabsorption in the proximal tubule is reduced by high sodium delivery (the inevitable consequence of high dietary sodium intake), calcium reabsorption falls in parallel. The result is calciuria: for every 100 mEq increase in daily sodium excretion, urinary calcium increases by approximately 25 mg/day, a clinically significant increment that raises calcium oxalate and calcium phosphate supersaturation. The typical Western diet contains 3,000 to 5,000 mg of sodium daily — two to three times the recommended maximum — and sodium reduction from this high baseline to below 2,300 mg/day consistently reduces urinary calcium by 10 to 30% in calcium stone formers.
High animal protein intake contributes to kidney stone risk through multiple mechanisms. Animal protein is rich in sulfur-containing amino acids (methionine, cysteine) that are oxidized on metabolism to sulfate, generating a net acid load. This acid load is buffered partly by mobilizing calcium carbonate from bone (raising urinary calcium), reduces renal tubular citrate reabsorption (lowering the urinary citrate that normally inhibits calcium crystallization), and reduces urinary ammonium excretion (acidifying the urine and predisposing to uric acid stone formation). Additionally, purines from animal protein are metabolized to uric acid, raising urinary uric acid. The net effect is that high animal protein diets simultaneously increase urinary calcium, increase urinary uric acid, reduce urinary citrate, and acidify the urine — a quadruple hit that elevates risk for both calcium and uric acid stones.
Low dietary calcium — counterintuitively — increases rather than decreases calcium stone risk. Dietary calcium normally binds oxalate in the intestinal lumen and carries it out in stool; when dietary calcium is restricted, more free oxalate remains for intestinal absorption, raising urinary oxalate and elevating calcium oxalate supersaturation. The correct dietary guidance for most calcium stone formers is to maintain adequate calcium intake from food sources (1,000 to 1,200 mg daily, consumed with meals) while moderating oxalate intake — the opposite of the “avoid calcium” advice still prevalent in some patient education materials. For a detailed breakdown of calcium oxalate stone dietary management, see the calcium oxalate stones article on this site.
High oxalate foods consumed in large amounts — spinach, rhubarb, almonds, cashews, peanuts, chocolate, bran, and strong tea — contribute significantly to urinary oxalate in some patients, particularly those with absorptive hyperoxaluria or enteric hyperoxaluria from gastrointestinal fat malabsorption. High fructose intake from sweetened beverages and ultra-processed foods independently raises urinary calcium and uric acid; large prospective cohort studies link sweetened beverage consumption to significantly increased kidney stone risk.
Medical Conditions That Raise Kidney Stone Risk
Obesity and metabolic syndrome are among the most significant population-level drivers of rising kidney stone incidence. Obese individuals have lower urinary pH (from insulin resistance–mediated reduction in renal ammonium excretion), higher urinary calcium (from adipose tissue–related metabolic acidosis promoting bone calcium mobilization), and higher urinary uric acid (from elevated purine catabolism). As BMI increases, kidney stone risk rises proportionally — individuals with BMI above 30 have a 2 to 3-fold higher stone risk than normal-weight individuals. Metabolic syndrome components — central obesity, insulin resistance, hypertriglyceridemia, low HDL, and hypertension — each independently associate with stone risk, and their combination produces a particularly unfavorable urinary environment for stone prevention.
Type 2 diabetes independently predicts kidney stone risk beyond its overlap with obesity and metabolic syndrome. Insulin resistance impairs the kidney tubule’s ability to excrete ammonium, the primary urinary acid buffer, resulting in persistently acidic urine that promotes uric acid crystallization. Uric acid stones account for up to 35 to 40% of kidney stones in patients with type 2 diabetes — approximately triple the rate in the general population.
Primary hyperparathyroidism — autonomous overproduction of parathyroid hormone (PTH) from a parathyroid adenoma — causes hypercalcemia and hypercalciuria through stimulated bone resorption and intestinal calcium absorption. Kidney stones (predominantly calcium phosphate and calcium oxalate) occur in approximately 15 to 20% of patients with primary hyperparathyroidism, and the condition should be screened for in any calcium stone former with elevated serum calcium. Parathyroidectomy is curative for the hyperparathyroidism and typically normalizes urinary calcium, substantially reducing stone recurrence risk.
Inflammatory bowel disease (Crohn’s disease in particular) predisposes to both calcium oxalate and uric acid stones. Fat malabsorption in Crohn’s disease leaves excess free fatty acids in the colon that bind calcium — the calcium that would normally complex with oxalate to prevent its absorption is sequestered by fat, leaving oxalate free for colonic absorption. This enteric hyperoxaluria dramatically raises urinary oxalate and calcium oxalate stone risk. Concomitant dehydration from chronic diarrhea and bicarbonate loss further promotes uric acid stone formation through reduced urinary volume and pH.
Renal tubular acidosis (RTA) — particularly Type 1 (distal) RTA — causes calcium phosphate stone formation through persistently alkaline urine (the kidney cannot adequately acidify the urine), hypocitraturia (from the alkaline intracellular environment reducing citrate excretion), and hypercalciuria. RTA should be considered in any patient with calcium phosphate stones, particularly those with simultaneously elevated urinary pH and very low urinary citrate.
Gout is associated with a 10 to 25% lifetime prevalence of kidney stones, predominantly uric acid but also calcium oxalate stones seeded by uric acid crystals (heterogeneous nucleation). Hyperuricemia — the serum uric acid elevation that causes gout — also elevates urinary uric acid, directly increasing stone-forming risk. For a detailed review of uric acid stone formation and treatment, see the uric acid stones guide on Horizon Health Guide.
Anatomical and Structural Risk Factors
Several anatomical variations predispose to kidney stone formation by impairing urinary drainage, promoting urinary stasis, or altering the renal microenvironment in ways that favor crystallization.
Medullary sponge kidney is a congenital renal malformation characterized by diffuse ectasia (dilation) of the renal collecting tubules, creating multiple small cystic spaces within the renal medulla that impair urine flow at the tubular level. Urinary stasis in the dilated tubules promotes crystal nucleation and aggregation; the condition is associated with recurrent calcium stones, nephrocalcinosis (diffuse calcium deposits throughout the kidney), and often distal RTA. Medullary sponge kidney accounts for approximately 20% of cases of recurrent calcium nephrolithiasis and should be considered in any patient with nephrocalcinosis on imaging.
Horseshoe kidney — the most common renal fusion anomaly, in which the lower poles of the kidneys are joined across the midline by a bridge of renal tissue — has impaired urinary drainage at the ureteropelvic junction due to the abnormal anatomy of the collecting system relative to the ureters. This relative obstruction promotes urinary stasis and a 20% lifetime kidney stone rate, compared to approximately 9 to 10% in the general population. Stones in horseshoe kidney are also more difficult to treat with shock wave lithotripsy (stone fragments have less distance to travel and more anatomical barriers to spontaneous passage) and may require percutaneous nephrolithotomy more readily than stones in normally positioned kidneys.
Genetic and Family History Risk Factors
A family history of kidney stones in a first-degree relative (parent or sibling) is one of the strongest predictors of stone risk in the general population, conferring approximately a 2.5-fold elevation in lifetime stone risk compared to individuals without a family history. The genetic contribution to kidney stone risk operates through multiple pathways: inherited differences in renal calcium transport (genes governing the epithelial calcium channels TRPV5 and TRPV6), oxalate metabolism (AGXT and GRHPR mutations causing primary hyperoxaluria), uric acid transport (SLC2A9, ABCG2), and cystine transport (SLC3A1 and SLC7A9 mutations causing cystinuria) all explain familial clustering of stone disease.
Cystinuria is the clearest example of a purely hereditary stone condition: it is caused by autosomal recessive mutations in amino acid transport genes that prevent normal renal reabsorption of cystine, lysine, ornithine, and arginine, resulting in massive cystinuria and recurrent stone formation from childhood. Other hereditary conditions with high stone penetrance include primary hyperoxaluria types 1, 2, and 3 (autosomal recessive enzyme defects causing massive endogenous oxalate overproduction), Dent’s disease (X-linked recessive renal tubular disorder with hypercalciuria and nephrocalcinosis), and familial hypercalciuric disorders. Patients with early-onset stone disease (before age 25), bilateral stones at presentation, nephrocalcinosis, or a family history of stone disease should be specifically evaluated for hereditary causes of nephrolithiasis.
Medications That Increase Kidney Stone Risk
Several commonly used medications raise kidney stone risk through pharmacological effects on urinary chemistry. Calcium and vitamin D supplements taken in excess increase urinary calcium; supplemental calcium not consumed with meals misses the oxalate-binding effect of meal-time calcium and generates a pure hypercalciuric load. High-dose vitamin C (above 1,000 mg per day) is metabolized to oxalate; doses above 2,000 mg per day significantly raise urinary oxalate and stone risk. Carbonic anhydrase inhibitors (topiramate, used for epilepsy and migraine prevention; acetazolamide, used for altitude sickness and glaucoma) inhibit urinary acidification, producing alkaline urine and hypocitraturia that promotes calcium phosphate stone formation — topiramate is the most common medication-associated cause of calcium phosphate stones encountered in younger adults. Uricosuric agents (probenecid) raise urinary uric acid and promote uric acid stone formation.
Understanding which medications carry stone risk allows both prescribers and patients to take anticipatory preventive measures — increasing fluid intake, adding urinary alkalinization when appropriate, and performing baseline and follow-up urinary chemistry evaluation in high-risk patients. For patients who require a stone-promoting medication for another condition, balancing the risk is a clinical decision rather than an automatic contraindication, but awareness of the risk enables appropriate monitoring. For a comprehensive guide on what to eat and avoid to reduce kidney stone risk across all stone types, see the diet and kidney stone prevention guide on Horizon Health Guide. Clinical reference guidelines from the American Urological Association, the NIDDK, and the StatPearls nephrolithiasis review provide further detail for clinicians and patients seeking evidence-based information.
Sources: AUA Kidney Stone Guidelines · NIDDK — Kidney Stones · StatPearls — Nephrolithiasis
Demographic and Non-Modifiable Risk Factors
Sex and age are among the strongest non-modifiable determinants of kidney stone risk. Men develop kidney stones approximately twice as frequently as women at every age, though the sex difference has narrowed as women’s rates have increased. The peak incidence age is 40 to 60 years in men and 50 to 70 years in women (postmenopausal women lose the protective effect of estrogen on urinary calcium and citrate, which narrows the sex gap in stone rates). Age-related reductions in fluid intake and mobility, along with age-related changes in renal tubular function, also contribute to higher stone rates in older adults. Men are more likely than women to form uric acid and calcium oxalate stones; women have higher rates of struvite stones (from more frequent urinary tract infections) and are more likely to have underlying structural abnormalities identified as contributing factors.
Race and ethnicity are associated with stone risk, though the mechanisms are complex and incompletely understood. Non-Hispanic white Americans have the highest kidney stone prevalence in the United States — approximately 12 to 13% lifetime prevalence — while Black Americans have approximately half the stone prevalence (6 to 7%), and Hispanic and Asian Americans fall between these extremes. Higher rates of lactose intolerance in some populations may contribute to lower dietary calcium intake (and paradoxically protective lower oxalate absorption), while dietary patterns, environmental heat exposure, and metabolic differences in urinary chemistry also contribute to racial and ethnic variation in stone risk. Notably, Black Americans have higher rates of hypertension, obesity, and type 2 diabetes, which would be expected to elevate their stone risk, but appear to have genetic protective factors — particularly related to more alkaline urinary pH on average — that partially offset these metabolic risks. The interaction between race/ethnicity, diet, metabolic risk factors, and stone genetics is an active area of research.
Prior kidney stone history is itself the strongest predictor of future stone episodes. Once a person has formed a kidney stone, the recurrence rate without preventive intervention is approximately 15 to 30% at 1 year, 50% at 5 years, and 70 to 80% at 10 years. The recurrence risk is higher for patients with identifiable metabolic risk factors on 24-hour urine evaluation, those with a family history of stones, those with younger age at first stone, and those who form non-calcium stone types (uric acid, cystine, struvite) — all of which carry higher intrinsic recurrence rates than idiopathic calcium stone disease.
Evaluating Your Personal Risk: The 24-Hour Urine Collection
For any patient who has formed a kidney stone — and for high-risk individuals who have not yet had a stone but have multiple risk factors — the 24-hour urine collection is the most informative single test for quantifying personal stone-forming risk. A 24-hour urine collection measures total urine volume, urinary pH, and the concentrations of calcium, oxalate, uric acid, citrate, sodium, creatinine, and phosphate. The results are compared to reference ranges derived from healthy non-stone-forming populations, and any values outside normal range — elevated calcium, elevated oxalate, elevated uric acid, low citrate, low volume, or abnormal pH — constitute an identified risk factor that can be specifically targeted by dietary modification or medication.
Two 24-hour collections on separate days are recommended over a single collection, because day-to-day variation in dietary intake and activity can cause a single collection to be unrepresentative of habitual urinary chemistry. The collections should be performed under the patient’s usual dietary conditions — not during a period of dietary restriction — so that the results reflect the urinary chemistry that produced the patient’s stones. The cost is modest (typically $100 to $250 per collection after insurance), and the information generated — a direct measurement of the specific metabolic abnormalities underlying the patient’s stone disease — is worth far more than this in terms of guiding prevention that actually works for that individual patient rather than generic advice.
The results of a 24-hour urine collection, interpreted by a urologist or nephrologist with stone expertise, generate a specific prevention plan: if hypercalciuria is identified, thiazide diuretics and sodium restriction are targeted; if hypocitraturia is identified, potassium citrate supplementation is indicated; if hyperoxaluria is identified, dietary oxalate restriction and optimal calcium intake with meals are emphasized; if hyperuricosuria with acidic urine is identified, alkalinization and purine restriction are the appropriate interventions. This targeted approach consistently outperforms generic advice in randomized trials of stone prevention interventions.
Reducing Your Risk: Practical Starting Points
For individuals concerned about kidney stone risk — whether because they have already had a stone or because they recognize multiple risk factors — several modifications provide meaningful risk reduction with relatively simple lifestyle changes:
Drinking enough fluid to produce at least 2 liters of urine per day is the single most effective and most universally applicable risk reduction strategy. Monitoring urine color (pale yellow to nearly clear is the target) provides a simple real-time guide to hydration adequacy. Reducing sodium intake — by reading food labels and avoiding high-sodium processed foods, canned foods, fast food, and restaurant meals — directly lowers urinary calcium and reduces calcium stone risk. Moderating animal protein intake and substituting plant protein sources for some animal protein reduces uric acid production and improves urinary citrate. Maintaining adequate dietary calcium at meals — rather than restricting it — protects against calcium oxalate stone formation by binding intestinal oxalate. Managing weight and metabolic risk factors (blood pressure, blood sugar, lipids) reduces the composite metabolic risk that drives calcium and uric acid stone formation in the increasingly prevalent metabolic syndrome stone patient. For further guidance on dietary modifications specific to kidney stone prevention, see the diet and kidney stone prevention guide on Horizon Health Guide. For specific hydration strategies, see the hydration and kidney stone prevention article. For understanding when a kidney stone requires medical treatment beyond passage, see the guide to when kidney stones need medical treatment.
I work construction in Phoenix and have had two kidney stones in three years. After the second one I finally did a 24-hour urine test and my urologist said everything was elevated — calcium, oxalate, AND uric acid — but my urine volume was only about 900 mL/day. In Phoenix summer I’m losing so much fluid through sweating that even though I thought I was drinking enough, I clearly wasn’t producing enough urine. This article explains exactly why I’m at high risk: high heat exposure occupational dehydration, high animal protein diet, and based on my blood work I’m borderline metabolic syndrome. Now I carry a water bottle with a liter-per-hour reminder on shifts.
This is an excellent overview of kidney stone risk factors. The section on medications is particularly important and underemphasized in most patient education. Topiramate-associated calcium phosphate stones are increasingly common as this medication is being prescribed more frequently for migraine prevention, weight loss, and psychiatric conditions — I see several patients per year who present with recurrent calcium phosphate stones and whose topiramate prescription was never flagged as a stone risk by the prescribing physician. The point about the 24-hour urine collection being the definitive risk assessment tool is correct — it transforms prevention from guessing to targeted intervention.
Thank you for highlighting the topiramate-associated stone risk, Dr. Hewitt — this is an important gap in patient education that spans neurology, psychiatry, and primary care. Topiramate’s carbonic anhydrase inhibition produces alkaline urine and hypocitraturia, a combination that promotes calcium phosphate crystallization, and the risk is dose-dependent. Patients starting topiramate who are already at elevated stone risk (prior stone history, family history, low fluid intake) should be counseled about this risk and their fluid intake assessed and optimized. Kevin, your situation — occupational dehydration in an extreme climate — is one of the most actionable stone risk scenarios precisely because the intervention is clear and effective: maintaining urine output above 2 liters per day on work days dramatically reduces your supersaturation risk regardless of what else is elevated.